摘要
目的探讨阿奇霉素联合痰热清治疗小儿肺炎支原体肺炎临床疗效。方法 2010年1月至2012年2月收治的肺炎支原体肺炎238例分为常规组122例,联合组116例观察两组临床疗效。结果阿奇霉素联合痰热清联合组总有效率93.10%,显著优于单用阿奇霉素常规组总有效率81.96%,经统计学分析,差异有统计学意义(P<0.05)。结论肺炎支原体肺炎主要表现为阵发性刺激性咳嗽、喘息;肺部体征较少,临床表现与特征不符,容易出现误诊,并且在对病情程度判断容易出现误判。小儿肺炎支原体肺炎治疗中应用阿奇霉素联合痰热清治疗具有显著提高临床疗效,减轻临床症状,缩短病程,促进疾病康复。
Objective To investigate the azithromycin united Tanreqing Injection in the treatment of pediatric mycoplasma pneumonia clinical curative effect.Methods From 2010 January-2012 year in February admits of Mycoplasma pneumoniae pneumonia in 238 patients were divided into normal group 122 cases,combined with group 116 cases observation of clinical curative effect of two sets.Results Azithromycin United Tanreqing combined group total effective rate 93.10%,significantly better than the conventional single azithromycin group total effective rate 81.96%,there were significant differences(P0.05).Conclusion Mycoplasma pneumoniae pneumonia mainly manifesting as paroxysmal irritating cough,wheeze;pulmonary signs less,clinical manifestations and characteristics of inconsistent,prone to misdiagnosis,and in the severity judgment easily miscarriage of justice.Mycoplasma pneumoniae pneumonia therapy azithromycin United Tanreqing therapy has significantly improve the clinical efficacy,alleviate the clinical symptoms,shorten the course of disease,promoting disease rehabilitation.
出处
《中国实用医药》
2012年第31期9-10,共2页
China Practical Medicine
关键词
阿奇霉素
痰热清
小儿肺炎支原体肺炎
临床观察
Tanreqing
Azithromycin
Mycoplasma pneumoniae pneumonia
Clinical observation